LPCN

Lipocine Inc.

1.57

USD

+0.04

+2.61%

Nov 06, 15:59 UTC -5

Closed

After-Market

1.55

-0.02

-0.96%

Lipocine Inc. (LPCN) Earnings

LPCN Earnings Reports

Positive Surprise Ratio

LPCN beat 29 of 43 last estimates.

67%

Next Report

Date of Next Report

Mar 08, 2027

Estimate for Q4 26 (Revenue/ EPS)

$165.75K

-$0.37

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-85.54%

-11.90%

Lipocine Inc. earnings per share and revenue

On Nov 04, 2026, LPCN reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.36 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 162.69 thousand, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.37 USD, with revenue projected to reach 165.75 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Guardian Pharmacy Services, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.30

Actual

$0.33

Surprise

+7.84%

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.02

Actual

$0.06

Surprise

+144.90%

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Collegium Pharmaceutical, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.89

Actual

$1.96

Surprise

+3.17%

Ironwood Pharmaceuticals, Inc. - Class A

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.32

Actual

$0.36

Surprise

+9.16%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.32

Actual

-$0.36

Surprise

-11.15%

Profound Medical Corp. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.18

Actual

-$0.21

Surprise

-11.41%

Akebia Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.03

Actual

-$0.04

Surprise

-6.95%

FAQ

What were Lipocine Inc.'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Lipocine Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Lipocine Inc.'s Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Lipocine Inc. expected to report next?

The next earning report is scheduled for Mar 08, 2027.

What are the forecasts for Lipocine Inc.'s next earnings report?

Based on -- analysts, Lipocine Inc. is expected to report EPS of -$0.37 and revenue of $165.75K for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.